BR112012026095A2 - métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. - Google Patents

métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.

Info

Publication number
BR112012026095A2
BR112012026095A2 BR112012026095A BR112012026095A BR112012026095A2 BR 112012026095 A2 BR112012026095 A2 BR 112012026095A2 BR 112012026095 A BR112012026095 A BR 112012026095A BR 112012026095 A BR112012026095 A BR 112012026095A BR 112012026095 A2 BR112012026095 A2 BR 112012026095A2
Authority
BR
Brazil
Prior art keywords
methods
virus
filter
impurities
virus stocks
Prior art date
Application number
BR112012026095A
Other languages
English (en)
Inventor
Amanda B Katz
Damon R Asher
Navid Z Khan
Ushma Mehta
Original Assignee
Emd Millipore Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012026095(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emd Millipore Corp filed Critical Emd Millipore Corp
Publication of BR112012026095A2 publication Critical patent/BR112012026095A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. a pureza e o título dos estoques de vírus utilizados para os estudos de eliminação de vírus apresentam uma influência significativa nos resultados do estudo, e têm um impacto em quão bem o modelo em escala reduzida representa o processo de pordução em grande escala. as impurezas em estoques de vírus são particularmente importantes nos testes de filtros para retenção de vírus pequenos, pois essas impurezas podem levar um filtro a entupir prematuramente, levando a uma subestimação da capacidade de passagem real do filtro e como consequência, um dimensionamento inapropriado da unidade de produção em grande escala. ademais, as impurezas também podem afetar os níveis observados de vírus eliminados por alterar os mecanismos de entupimento e passagem subsequente do fluido através do filtro para vírus. descritos aqui são métodos para preparar, produzir e usar estoques de vírus de alta pureza que têm altos títulos.
BR112012026095A 2010-04-14 2011-04-08 métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. BR112012026095A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32422010P 2010-04-14 2010-04-14
PCT/US2011/031747 WO2011130119A2 (en) 2010-04-14 2011-04-08 Methods of producing high titer, high purity virus stocks and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112012026095A2 true BR112012026095A2 (pt) 2015-09-15

Family

ID=44148425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026095A BR112012026095A2 (pt) 2010-04-14 2011-04-08 métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.

Country Status (9)

Country Link
US (1) US9644187B2 (pt)
EP (1) EP2377927B1 (pt)
JP (3) JP2013523175A (pt)
KR (1) KR101549296B1 (pt)
CN (1) CN102985536B (pt)
BR (1) BR112012026095A2 (pt)
ES (1) ES2736166T3 (pt)
SG (1) SG184833A1 (pt)
WO (1) WO2011130119A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985536B (zh) 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
IN2014DN06925A (pt) * 2012-03-13 2015-04-10 Emd Millipore Corp
JP5980947B2 (ja) * 2012-11-22 2016-08-31 旭化成メディカル株式会社 高感染価のパルボウイルスの生産方法
KR20150118155A (ko) * 2013-02-22 2015-10-21 에이전시 포 사이언스, 테크놀로지 앤드 리서치 음성 하전된 입자들을 갖는 바이러스 제제들의 크로마토그래피 정제
WO2015036917A2 (en) 2013-09-10 2015-03-19 MockV Solutions Methods and kits for quantifying the removal of mock virus particles from a purified solution
KR102036467B1 (ko) * 2015-11-06 2019-10-24 아사히 가세이 메디컬 가부시키가이샤 고감염가 또한 고순도의 파보바이러스의 생산 방법
DE102016005049B4 (de) 2016-04-26 2020-06-18 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung des logarithmischen Reduktionswertes LRV eines Größenausschlussfilters
EP3299454A1 (en) * 2016-09-21 2018-03-28 Deutsches Krebsforschungszentrum Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium
EP3141611A3 (en) * 2016-10-21 2017-05-10 Bayer Healthcare LLC Validation of continuous viral clearance
US10961512B2 (en) * 2017-04-17 2021-03-30 Dao-Yao He Compositions and kits for purification of viral particles from host cells
KR102453351B1 (ko) 2017-07-05 2022-10-07 에스케이바이오사이언스(주) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
EP3446710A1 (en) * 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
CN108841794B (zh) * 2018-06-08 2021-11-30 苏州良辰生物医药科技有限公司 一种病毒原液的制备方法
CN115176037A (zh) * 2020-02-28 2022-10-11 旭化成医疗株式会社 病毒清除性能的评价方法
WO2021261451A1 (ja) * 2020-06-24 2021-12-30 旭化成メディカル株式会社 タンパク質含有溶液の評価方法
JPWO2022203044A1 (pt) 2021-03-26 2022-09-29
WO2022252098A1 (zh) * 2021-05-31 2022-12-08 中国科学院深圳先进技术研究院 噬菌体制剂的制备方法、药物组合物以及应用
JP2023003771A (ja) * 2021-06-24 2023-01-17 株式会社島津製作所 ウイルス試料の濃縮方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622663A (en) 1968-06-13 1971-11-23 American Home Prod Purification of viruses on treated calcium dihydrogen orthophosphate monohydrate adsorbent
US3919044A (en) 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
SU579309A1 (ru) 1973-11-16 1977-11-05 Ленинградский Политехнический Институт Им.М.И.Калинина Способ получени вакцины
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
JPS6147185A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147186A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US6265149B1 (en) 1986-01-22 2001-07-24 Institut Pasteur In vitro diagnostic methods and kits for the detection of HIV-2-specific antibodies
US5824482A (en) 1986-06-23 1998-10-20 Institut Pasteur Purification, cloning, and characterization of a novel human immunodeficiency virus LAVMAL
US4814268A (en) 1986-10-06 1989-03-21 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US4859597A (en) * 1987-07-27 1989-08-22 Igene Biotechnology, Inc. Production of phage and phage-associated lysin
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5268292A (en) 1988-06-27 1993-12-07 Robertson Betty H Reproducible generation of high yields of hepatitis A virus by cell culture
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US5719051A (en) 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen
DE4003543A1 (de) 1990-02-06 1991-08-08 Orpegen Med Molekularbioforsch Verfahren zur abreicherung von viren in loesungen und zur bestimmung der abreicherungsrate von viren
US6709811B1 (en) 1990-05-24 2004-03-23 The United States Of America As Represented By The Department Of Health And Human Services Versatile reagent for detecting murine leukemia viruses
ATE105857T1 (de) 1990-06-15 1994-06-15 Innogenetics Nv Siv cpz-ant retrovirus und seine anwendungen.
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5658779A (en) 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
CA2107732C (en) 1992-10-06 2003-04-08 Lutz G. Gurtler Retrovirus from the hiv group and its use
ATE189697T1 (de) 1994-03-22 2000-02-15 Immune Response Corp Inc Die hocheffiziente herstellung und isolierung von viruspartikeln
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
DE69534166T2 (de) 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
CA2625279A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
EP0884383A4 (en) 1996-02-29 2001-12-05 Takara Shuzo Co METHOD FOR CLEANING AND REMOVING VIRUSES.
CA2250041A1 (en) 1996-03-29 1997-10-09 University Of Otago Parapoxvirus vectors
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
EP0968284B1 (en) * 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
ZA982950B (en) 1997-04-08 1998-10-19 Merck & Co Inc Stabilized human papillomavirus formulations
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
US6037456A (en) 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
US5994134A (en) 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
BR9913026A (pt) 1998-08-14 2001-09-25 Merck & Co Inc Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
WO2000011149A1 (en) 1998-08-24 2000-03-02 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
CA2348382C (en) 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
CN1087032C (zh) * 1998-12-14 2002-07-03 彭朝晖 一种生产重组腺病毒的方法
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
AU779267B2 (en) * 1998-12-31 2005-01-13 Centelion S.A.S. Method for separating viral particles
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US6316185B1 (en) 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
AU1811301A (en) 1999-12-02 2001-06-12 General Hospital Corporation, The Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
US20010043916A1 (en) 1999-12-29 2001-11-22 Mcneilly David S. Method using filtration aids for the separation of virus vectors from nucleic acids and other cellular contaminants
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
US6884613B2 (en) 2000-08-25 2005-04-26 The General Hospital Corporation Selective precipitation of viruses
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
WO2003085138A1 (en) 2002-03-29 2003-10-16 Merck & Co., Inc. Methods of virus production
EP1492890A4 (en) 2002-03-29 2006-10-18 Merck & Co Inc METHODS OF LARGE SCALE PRODUCTION OF ADENOVIRUS AND ADENOVIRUS SEMEN COLLECTIONS
ES2323454T5 (es) 2002-04-30 2012-11-14 Oncolytics Biotech Inc. Procedimiento mejorado de purificación de virus
AU2003229060A1 (en) 2002-05-14 2003-12-02 Merck And Co., Inc. Methods of adenovirus purification
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
AU2003237528A1 (en) 2002-06-07 2003-12-22 Kentucky Bioprocessing, Llc Flexible vaccine assembly and vaccine delivery platform
WO2004000220A2 (en) 2002-06-21 2003-12-31 Genetix Pharmaceuticals, Inc. Methods for purifying viral particles for gene therapy
US20060228334A1 (en) * 2002-07-10 2006-10-12 Manuel Rosa-Calatrava Modified adenoviral fiber with ablated to cellular receptors
KR101044538B1 (ko) 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 무혈청 조건하에서 일차세포의 배양 및 바이러스의 증식방법
US20050009168A1 (en) 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
CA2529053A1 (en) 2003-06-18 2004-12-29 Onyx Pharmaceuticals, Inc. Method for purifying virus
AU2003272868A1 (en) 2003-10-15 2005-04-27 Agtc Gene Technology Company Ltd. Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors
CA2551026A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
DK1780269T3 (da) 2004-02-23 2009-10-12 Crucell Holland Bv Virusrensningsmetoder
KR20070060049A (ko) 2004-05-20 2007-06-12 아이디 바이오메디칼 코포레이션 인플루엔자 백신의 제조방법
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
DE102004049290A1 (de) 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
WO2006052302A2 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying adenoviral vectors
US20060281075A1 (en) 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
US7344839B2 (en) 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
DE602006003420D1 (de) 2005-04-11 2008-12-11 Crucell Holland Bv Virusreinigung mit ultrafiltration
DE102005047301B4 (de) 2005-09-30 2009-04-16 Sartorius Stedim Biotech Gmbh Verfahren zum Nachweis der Virenabreicherung für die Validierung von Filtern und Filtrationsprozessen
WO2007059473A2 (en) 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
US7754421B2 (en) 2005-11-18 2010-07-13 National Research Council Of Canada Detection of intact recombinant viruses
KR101157176B1 (ko) 2005-12-20 2012-06-20 삼성전자주식회사 세포 또는 바이러스의 농축 또는 정제용 미세유동장치 및방법
ES2400235T3 (es) * 2006-04-28 2013-04-08 The Trustees Of The University Of Pennsylvania Método de producción escalable de AAV
US7851196B2 (en) 2006-05-01 2010-12-14 The Regents Of The University Of California Methods for purifying adeno-associated virus particles
EP2073839B1 (en) * 2006-09-01 2016-10-19 Bharat Biotech International Limited A vaccine for chikungunya virus infection
JP2010512748A (ja) 2006-12-15 2010-04-30 シェーリング−プラウ・リミテッド インフルエンザウイルスを培養物中で複製するための方法
WO2008109721A1 (en) * 2007-03-06 2008-09-12 Introgen Therapeutics, Inc. Chromatographic methods for assessing adenovirus purity
KR101576219B1 (ko) * 2007-03-14 2015-12-10 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
EP2134757A2 (en) 2007-03-27 2009-12-23 University of Maryland, College Park Imprinted polymeric materials for binding various targets such as viruses
BRPI0811499B8 (pt) 2007-05-04 2021-05-25 Baxalta GmbH métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
CN102257134B (zh) * 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
CN102985536B (zh) 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
US9651469B1 (en) * 2016-01-27 2017-05-16 General Electric Company Electrostatic particle sensor

Also Published As

Publication number Publication date
US20120088228A1 (en) 2012-04-12
JP2017195897A (ja) 2017-11-02
SG184833A1 (en) 2012-11-29
WO2011130119A2 (en) 2011-10-20
WO2011130119A3 (en) 2012-03-29
JP6284500B2 (ja) 2018-02-28
CN102985536A (zh) 2013-03-20
EP2377927A1 (en) 2011-10-19
US9644187B2 (en) 2017-05-09
WO2011130119A8 (en) 2011-12-29
CN102985536B (zh) 2017-12-05
EP2377927B1 (en) 2019-05-22
JP6522054B2 (ja) 2019-05-29
JP2015126757A (ja) 2015-07-09
ES2736166T3 (es) 2019-12-26
JP2013523175A (ja) 2013-06-17
KR101549296B1 (ko) 2015-09-01
KR20130020954A (ko) 2013-03-04

Similar Documents

Publication Publication Date Title
BR112012026095A2 (pt) métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
BR112018001995A2 (pt) moléculas de ácido nucleico artificial
BR112013029834A2 (pt) vacinas individualizadas para câncer
BR112015019731A2 (pt) método para testar vários conjuntos protetores espacialmente distribuídos de uma rede alimentadora de corrente, bem como sistema de teste correspondente
BR112014026383A2 (pt) derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl1
BR112014018025A8 (pt) Material de filtro de cigarro; dispositivo para fumar; e processo para produzir uma estopa de acetato de celulose substituído
BR112016021678A2 (pt) método e sistema para determinar uma janela de peso de lama em um poço, e, meio legível por computador.
BR112014018021A8 (pt) Material de filtro de cigarro; dispositivo para fumar; e processo para produzir uma estopa de acetato de celulose substituído
BRPI0821034A8 (pt) Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação
BR112015024119A2 (pt) polipeptídeos tendo atividade de fosfolipase a e polinucleotídeos que os codificam
BR112013025459A2 (pt) análise de alto rendimento de bordas de transgenes
BR112016011519A8 (pt) Nanofibras à base de derivados de éster de ácido hialurônico e seu sal, método de síntese de nanofibras, método de fotocura de nanofibras, nanofibras fotocuradas à base de derivados de ácido hialurônico, preparação compreendendo nanofibras fotocuradas
BR112015010399A2 (pt) método e kit para a determinação de cobre livre no soro
BR112015001405A2 (pt) sistema e método de gerenciamento de compressor de multicorrente
BR112012028945A2 (pt) uso de marcadores específicos do gene brown midrib-3 no milho para a incorporação de traços
BR112012027138A2 (pt) processo de cereal estraído de girassóis
BR112014027223A2 (pt) métodos e sistemas para fornecer informações de atualização de descrição de dispositivo de um instrumento de campo
BR112014014423A2 (pt) sistema e método para gerar instruções de marcação de máquina
BR112012022928A2 (pt) beta-hidroxialquilamidas, processo para sua produção, bem como seu uso
BR112014018022A8 (pt) Composição; método; e composição adesiva
BR112017013160A2 (pt) Novos acetais de 1-(3,3-dimetilciclohex-1-enil) etanona, seu método de preparação e também seu uso na perfumaria
AR090110A1 (es) Factor de transcripcion helianthus annuus modificado
GORAKSHNATH et al. Characterization of Binding Mode of the Heterobiaryl gp120 Inhibitor in HIV-1 Entry: A Molecular Docking and Dynamics Simulation Study
Murre The European Financial Transactions Tax: Issues for Derivatives, Structured Products and Securitization
BR112016001842A2 (pt) métodos, aparelhos, e programa de computador

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: EMD MILLIPORE CORPORATION (US)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2717 DE 31-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.